永安药业(002365) - 2023 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2023 was ¥311,166,729.63, a decrease of 24.51% compared to ¥412,209,105.79 in the same period last year[5] - Net profit attributable to shareholders was ¥14,983,070.77, down 70.38% from ¥50,589,943.61 year-on-year[5] - Basic earnings per share decreased by 69.19% to ¥0.0508 from ¥0.1649 in the same period last year[5] - Total profit for the period was ¥15,059,977.50, down 73.83% from ¥57,545,947.50 in the same period last year[10] - The total comprehensive income for Q1 2023 was CNY 12,798,926.77, down from CNY 49,907,047.08 in Q1 2022, a decrease of about 74.4%[23] - The net profit for Q1 2023 was CNY 13,694,733.08, down from CNY 50,083,816.82 in the same period last year, indicating a decline of about 72.7%[23] Cash Flow - The net cash flow from operating activities increased by 85.05% to ¥48,405,966.87, compared to ¥26,157,813.52 in the previous year[5] - The operating cash flow for Q1 2023 was CNY 48,405,966.87, an increase from CNY 26,157,813.52 in Q1 2022, showing a growth of approximately 84.5%[26] - The net cash flow from investment activities was -86,991,761.53 RMB, a decrease of 265.33% compared to the previous period, mainly due to an increase in financial management scale[11] - The net cash flow from financing activities was -30,082,708.33 RMB, a decrease of 438.82% compared to the previous period, primarily due to the repayment of bank loans by subsidiaries[11] - The company reported a net cash outflow from financing activities of -CNY 30,082,708.33 in Q1 2023, compared to a net inflow of CNY 8,878,793.95 in Q1 2022[27] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,432,265,076.91, a slight increase of 0.33% from ¥2,424,179,175.81 at the end of the previous year[5] - Cash and cash equivalents at the end of Q1 2023 were CNY 204,759,330.06, down from CNY 274,716,138.81 at the beginning of the year[20] - Total liabilities decreased to CNY 314,193,716.91 from CNY 321,173,058.41 at the beginning of the year[20] - Inventory as of March 31, 2023, was CNY 156,762,107.37, an increase from CNY 149,597,978.67 at the beginning of the year[20] Expenses - The company reported a significant decline in sales expenses, which rose by 96.96% to ¥40,395,430.67, primarily due to increased market operations and promotional efforts[10] - Total operating costs for Q1 2023 were CNY 309,419,184.44, down 13.4% from CNY 357,245,810.45 year-on-year[22] - Research and development expenses for Q1 2023 were CNY 9,951,522.52, consistent with CNY 9,935,149.46 in Q1 2022[22] Investment and Projects - The company reported a significant increase in construction in progress, which rose by 84.23% to ¥94,970,203.47, mainly due to investments in a 40,000-ton taurine project[10] - The company plans to expand its annual production capacity of taurine food additives by 40,000 tons, with an investment of 250 million RMB, and is currently progressing with safety assessments[15] - The company has signed a sales operation transfer agreement with Jamieson Laboratories Ltd., which includes a payment of 8.95 million CAD for asset transfer and support services[14] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 30,995, with no preferred shareholders having restored voting rights[12] - The largest shareholder, Chen Yong, holds 21.54% of the shares, amounting to 63,468,000 shares[12] Legal Matters - The company is actively responding to a patent infringement lawsuit filed in the U.S. and has engaged a U.S. law firm to protect its rights[16] - The company has not disclosed any related party transactions involving the top ten shareholders[12] Financial Gains and Losses - The company experienced a 39.34% decrease in investment income, amounting to ¥1,891,449.70 compared to ¥3,118,130.80 in the previous year[10] - The company reported a significant increase in financial asset fair value gains of CNY 6,545,418.74 compared to a loss of CNY 791,395.69 in the previous year[22]